AveXis’ Zolgensma gene therapy yields desired results in SMA trials

This article was originally published here

Zolgensma also delivered the desired results in patients who were given presymptomatic treatment and also in certain participants aged over five years. The gene therapy could sustain durability

The post AveXis’ Zolgensma gene therapy yields desired results in SMA trials appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply